The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement
disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment …

Parkinson's disease (PD) is the second most common neurodegenerative disease. PD
patients exhibit motor symptoms such as akinesia/bradykinesia, tremor, rigidity, and postural …

Scientific evidence has demonstrated the power of physical exercise in the prevention and
treatment of numerous chronic and/or age-related diseases, such as musculoskeletal …

Although levodopa remains the most efficacious symptomatic therapy for Parkinson disease
(PD), management of levodopa treatment during the advanced stages of the disease is …

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects motor and
cognition functions. The etiology of Parkinson's disease remains largely unknown, but …

Midbrain dopamine (mDA) neurons can be replaced in patients with Parkinson's disease
(PD) in order to provide long-term improvement in motor functions. The limited capacity for …

Neurotrophic factors (NTFs) are small secreted proteins that support the development,
maturation and survival of neurons. NTFs injected into the brain rescue and regenerate …

Synucleinopathies are a group of neurodegenerative disorders caused by the accumulation
of toxic species of α-synuclein. The common clinical features are chronic progressive …

Background Cerebral dopamine neurotrophic factor (CDNF) is an unconventional
neurotrophic factor that protects dopamine neurons and improves motor function in animal …